I now have comprehensive data from multiple pharmacology textbooks. Let me compile the complete viva Q&A.
Hematinics - Viva Questions & Answers (Exam-Oriented)
Sources: Katzung's Basic & Clinical Pharmacology 16e, Lippincott Illustrated Reviews Pharmacology, Goodman & Gilman's Pharmacological Basis of Therapeutics
SECTION 1: IRON
Q1. What is the most common cause of chronic anemia?
Iron deficiency. It produces a microcytic, hypochromic anemia due to insufficient hemoglobin synthesis.
Q2. What is the role of iron in the body?
Iron forms the nucleus of the iron-porphyrin heme ring, which combines with globin chains to form hemoglobin. Hemoglobin reversibly binds oxygen for tissue delivery. Iron-containing heme is also essential in myoglobin, cytochromes, and other proteins.
Q3. What are the common causes of iron deficiency?
- Acute or chronic blood loss (most common in adults - GI, menstrual)
- Menstruation (most common in premenopausal women)
- Pregnancy (increased demand)
- Dietary deficiency (rare in developed world)
- Malabsorption (celiac disease, post-gastrectomy)
- Rapid growth in infants/children
- Katzung 16e, Lippincott
Q4. What are the unique clinical features of iron deficiency anemia beyond typical anemia symptoms?
- Pica - craving for ice (pagophagia), dirt, paper
- Koilonychia (spoon-shaped nails)
- Angular stomatitis / cheilosis (cracking at corners of mouth)
- Glossitis (smooth sore tongue)
- Plummer-Vinson syndrome (iron deficiency + dysphagia + esophageal web)
- Lippincott Pharmacology
Q5. In what form is iron absorbed, and where?
- Iron must be in the reduced ferrous (Fe²⁺) form for absorption
- Gastric acid maintains iron in this reduced soluble form
- Absorbed in the duodenum (proximal small intestine)
- The amount absorbed is inversely proportional to body iron stores (regulated by hepcidin)
- Lippincott Pharmacology
Q6. What is the role of hepcidin in iron regulation?
Hepcidin is a peptide hormone produced by the liver. It inhibits ferroportin (the iron export protein on enterocytes and macrophages), thereby reducing iron absorption from the gut and iron release from stores. In iron deficiency, hepcidin levels fall, increasing iron absorption. In inflammation/iron overload, hepcidin rises, reducing iron release.
Q7. How is iron stored and transported in the body?
- Stored as ferritin (iron-protein complex) in intestinal mucosal cells, liver, spleen, and bone marrow; also as hemosiderin
- Transported in plasma bound to transferrin (a beta-globulin transport protein)
- Transferrin delivers iron to bone marrow for hemoglobin synthesis
- Lippincott Pharmacology, Katzung 16e
Q8. What are the lab findings in iron deficiency anemia?
| Parameter | Finding |
|---|
| Serum iron | ↓ |
| Serum ferritin | ↓ (earliest and most sensitive) |
| TIBC (Total Iron Binding Capacity) | ↑ |
| Transferrin saturation | ↓ (<16%) |
| MCV | ↓ (microcytic) |
| Peripheral smear | Hypochromic, microcytic RBCs, target cells |
| Reticulocyte count | Low (inadequate production) |
Q9. Name the oral iron preparations with their elemental iron content.
| Preparation | Elemental Iron Content |
|---|
| Ferrous sulfate | ~20% (65 mg per 325 mg tablet) |
| Ferrous fumarate | ~33% (highest per mg) |
| Ferrous gluconate | ~12% |
| Carbonyl iron | ~99% pure iron |
| Polysaccharide-iron complex | Variable |
The recommended dose is 60-120 mg/day of elemental iron in divided doses.
Q10. Why is ferrous sulfate preferred over ferric iron salts orally?
Ferrous (Fe²⁺) is the more soluble, better-absorbed form. Ferric (Fe³⁺) salts are poorly soluble at intestinal pH and have much lower bioavailability. Gastric acid converts ferric to ferrous form, aiding absorption.
Q11. What factors increase or decrease oral iron absorption?
| Increases Absorption | Decreases Absorption |
|---|
| Ascorbic acid (Vitamin C) - reduces Fe³⁺ to Fe²⁺ | Antacids, PPIs (raise gastric pH) |
| Acidic environment (HCl) | Tetracyclines, fluoroquinolones (chelation) |
| Empty stomach | Calcium, phosphates |
| Iron deficiency state | Tannins (tea), phytates (cereals) |
| H. pylori infection |
Q12. When should parenteral iron be used?
- Malabsorption (celiac, inflammatory bowel disease, post-gastrectomy)
- Intolerance to oral iron (severe GI side effects)
- Non-compliance with oral therapy
- Hemodialysis patients on erythropoietin (need for rapid iron delivery)
- Inflammatory bowel disease where oral iron worsens mucosal inflammation
- Katzung 16e, Lippincott
Q13. Name the parenteral iron preparations.
- Iron dextran (IM or IV; risk of anaphylaxis - test dose required)
- Sodium ferric gluconate (IV; safer, fewer reactions)
- Iron sucrose (IV; used in CKD/dialysis patients)
- Ferric carboxymaltose (IV; single large dose possible)
- Ferumoxytol (IV; rapid infusion)
- Katzung 16e, Lippincott
Q14. What is the major danger of parenteral iron dextran?
Anaphylaxis/anaphylactoid reactions - a test dose of 0.5 mL (25 mg) must be given first, with resuscitation facilities available. Iron dextran carries the highest risk among parenteral iron preparations. Delayed reactions (arthralgias, myalgias, fever) also occur.
Q15. What are the side effects of oral iron?
- GI disturbances - most common: nausea, vomiting, constipation, diarrhea, epigastric pain
- Black discoloration of stools (harmless; important to distinguish from melena)
- Liquid preparations can stain teeth temporarily
- Higher doses paradoxically decrease absorption and worsen side effects
- Every-other-day dosing emerging as effective with fewer side effects
- Lippincott Pharmacology
Q16. How long does it take to correct iron deficiency anemia and when should treatment be stopped?
- Hemoglobin rises by ~1-2 g/dL per week after therapy begins
- Reticulocytosis appears at 3-5 days (first sign of response)
- Continue iron for 3-6 months after Hb normalizes to replenish body stores
- Katzung 16e
Q17. What is iron overload (hemosiderosis/hemochromatosis) and how is it treated?
Excess iron deposits in liver, heart, pancreas, skin ("bronze diabetes"). Iron dextran overdose or repeated transfusions cause hemosiderosis. Treatment: Deferoxamine (IV/SC chelating agent), deferasirox (oral chelator), or phlebotomy.
SECTION 2: FOLIC ACID
Q18. What is the role of folic acid in erythropoiesis?
Folic acid (as tetrahydrofolate, THF) is essential for one-carbon transfer reactions required for synthesis of:
- Thymidylate (dTMP) - essential for DNA synthesis
- Purines - for DNA and RNA synthesis
Without folate, DNA synthesis is impaired in rapidly dividing cells (including erythroblasts), leading to megaloblastic anemia.
- Katzung 16e
Q19. Describe the folate absorption pathway.
- Dietary folate (as polyglutamates) is converted to monoglutamates by intestinal conjugases
- Absorbed in the proximal jejunum
- Converted to N5-methyltetrahydrofolate (the main plasma form)
- Stored primarily in the liver (body stores last ~3-4 months only - much less than B12)
- Daily requirement: 50-200 mcg (400 mcg in pregnancy)
- Katzung 16e
Q20. What are common causes of folate deficiency?
- Dietary deficiency (most common - alcoholics, elderly, poor diet)
- Pregnancy/lactation (increased demand - commonest cause in pregnancy)
- Malabsorption (celiac disease, tropical sprue)
- Drugs - methotrexate (inhibits dihydrofolate reductase), trimethoprim, phenytoin, sulfonamides
- Hemolytic anemia (increased cell turnover demands more folate)
- Katzung 16e
Q21. What is the mechanism by which methotrexate causes folate deficiency?
Methotrexate inhibits dihydrofolate reductase (DHFR), the enzyme that converts dihydrofolate (DHF) to tetrahydrofolate (THF). Without THF, one-carbon transfers for dTMP and purine synthesis are blocked, impairing DNA synthesis. Leucovorin (folinic acid/citrovorum factor) bypasses DHFR and is used as a "rescue" agent.
Q22. Why is folate supplementation important in pregnancy?
Neural tube defects (spina bifida, anencephaly) are strongly linked to folate deficiency in early pregnancy. 400 mcg/day periconceptionally (1 mg/day if prior NTD history) prevents NTDs. Folate is needed for rapid cell division in early neurulation.
Q23. Blood smear in folate/B12 deficiency - what do you see?
- Macrocytic, megaloblastic anemia
- Hypersegmented neutrophils (>5 lobes in >5% neutrophils; or any cell with 6+ lobes) - pathognomonic
- Macro-ovalocytes
- Elevated MCV (>100 fL)
- Pancytopenia in severe cases
SECTION 3: VITAMIN B12 (CYANOCOBALAMIN)
Q24. What is intrinsic factor and why is it important?
Intrinsic factor (IF) is a glycoprotein secreted by gastric parietal cells. Dietary B12 (liberated in stomach/duodenum) binds to IF, and the IF-B12 complex is absorbed via specific receptors in the terminal ileum. Without IF (pernicious anemia, gastrectomy), B12 cannot be absorbed.
Q25. What are the two active coenzyme forms of vitamin B12 and their functions?
| Coenzyme | Reaction |
|---|
| Methylcobalamin | Transfers methyl group from N5-methylTHF to homocysteine → methionine (links B12 & folate metabolism) |
| Deoxyadenosylcobalamin | Converts methylmalonyl-CoA → succinyl-CoA (via methylmalonyl-CoA mutase) |
Deficiency of deoxyadenosylcobalamin → methylmalonic acid accumulates → demyelination of posterior and lateral columns of spinal cord (subacute combined degeneration of spinal cord - SACD).
Q26. Explain the "methylfolate trap" concept.
In B12 deficiency, the conversion of N5-methylTHF to THF is blocked (because methylcobalamin, the required co-factor, is absent). Folate becomes "trapped" as N5-methylTHF, which cannot be used for DNA synthesis. This is why:
- B12 deficiency causes megaloblastic anemia (via functional folate deficiency)
- Large doses of folic acid can partially correct the anemia of B12 deficiency (folic acid can be reduced directly to THF by DHFR)
- BUT folic acid does NOT correct the neurological damage of B12 deficiency - masking B12 deficiency with folate is dangerous
Q27. What are the neurological features of B12 deficiency (SACD)?
Subacute Combined Degeneration of the Spinal Cord (SACD):
- Posterior column involvement: loss of vibration sense, proprioception, sensory ataxia
- Lateral column (corticospinal) involvement: UMN signs - spasticity, hyperreflexia, extensor plantar
- Peripheral neuropathy (also common)
- Neuropsychiatric features: megaloblastic madness, dementia
The mechanism is failure of myelin synthesis due to methylmalonyl-CoA accumulation and impaired methionine synthesis.
- Katzung 16e
Q28. What investigations help differentiate B12 deficiency from folate deficiency?
| Feature | B12 Deficiency | Folate Deficiency |
|---|
| Serum B12 | ↓ | Normal |
| Serum folate | Normal (may be high) | ↓ |
| RBC folate | ↓ (functional) | ↓ |
| Methylmalonic acid | ↑ (specific for B12) | Normal |
| Homocysteine | ↑ | ↑ |
| Neurological features | Present (SACD) | Absent |
| Schilling test | Abnormal | Normal |
Q29. What is pernicious anemia?
An autoimmune condition in which antibodies destroy:
- Anti-parietal cell antibodies (against H+/K+ ATPase)
- Anti-intrinsic factor antibodies (most specific)
This leads to gastric atrophy, loss of parietal cells, absent IF → B12 malabsorption → megaloblastic anemia + SACD. Associated with other autoimmune diseases (thyroid, type 1 DM, vitiligo).
Q30. How is B12 deficiency treated?
- Pernicious anemia / malabsorption: IM cyanocobalamin 1000 mcg daily for 7 days, then weekly for 4 weeks, then monthly for life
- Dietary deficiency (vegans): oral B12 1000 mcg/day (high-dose oral is sufficient as some absorption occurs by passive diffusion even without IF)
- Hydroxocobalamin (preferred in UK): longer half-life, retained better in body
- Katzung 16e
Q31. Why should folic acid NOT be given alone in B12 deficiency?
Folic acid corrects the hematological findings (anemia) but does NOT correct the neurological damage (SACD). Giving folate alone masks the B12 deficiency and allows neurological deterioration to continue - this is a classic exam trap. Always diagnose and treat B12 deficiency specifically.
SECTION 4: ERYTHROPOIETIN (EPO)
Q32. What is erythropoietin and where is it produced?
Erythropoietin (EPO) is a glycoprotein hormone produced mainly by peritubular cells of the kidney (85%) and liver (15%) in response to tissue hypoxia. It stimulates erythroid progenitor cell differentiation and proliferation in bone marrow.
Q33. Name the recombinant EPO preparations and their uses.
- Epoetin alfa (Epogen, Procrit): given SC or IV
- Darbepoetin alfa (Aranesp): longer half-life (hyperglycosylated form), less frequent dosing
- Epoetin beta: similar to epoetin alfa
- Methoxy polyethylene glycol-epoetin beta (Mircera): continuous erythropoietin receptor activator, monthly dosing
Indications:
- Anemia of chronic kidney disease (CKD) - most common indication
- Cancer chemotherapy-induced anemia
- HIV patients on zidovudine (AZT)
- Pre-surgical autologous blood collection
- Lippincott Pharmacology
Q34. What is the major adverse effect of erythropoietin therapy?
- Hypertension - most common; requires BP monitoring
- Thrombosis / thromboembolic events (increased blood viscosity from rising Hct)
- Pure red cell aplasia - rare but serious; anti-EPO antibodies develop; treat by stopping EPO and immunosuppression
- Tumor progression risk (EPO receptors may be expressed on some tumor cells)
- Iron deficiency (functional, from increased utilization) - must ensure adequate iron stores
Important: Target Hb should not exceed 11-12 g/dL in CKD to avoid cardiovascular risks.
- Lippincott Pharmacology, Katzung 16e
SECTION 5: HYDROXYUREA & SICKLE CELL
Q35. How does hydroxyurea help in sickle cell disease?
Hydroxyurea acts through poorly defined pathways (involving nitric oxide) to increase fetal hemoglobin (HbF) production. HbF does not participate in sickling and inhibits polymerization of HbS, thereby:
- Reducing vaso-occlusive crises
- Decreasing acute chest syndrome episodes
- Reducing frequency of painful crises and transfusion requirements
Mechanism as a chemotherapy drug: inhibits ribonucleotide reductase, depleting deoxyribonucleotides and arresting cells in S-phase.
Q36. What are the adverse effects of hydroxyurea?
- Myelosuppression (hematopoietic depression) - dose-limiting
- GI disturbances
- Teratogenicity - contraindicated in pregnancy
- Skin changes (leg ulcers with long-term use)
- Katzung 16e
SECTION 6: HIGH-YIELD RAPID-FIRE SUMMARY
Q37. Key "Why" questions:
| Question | Answer |
|---|
| Why is vitamin C given with iron? | Ascorbic acid reduces Fe³⁺ → Fe²⁺ and maintains acidic pH, increasing absorption |
| Why is ferritin the earliest lab indicator of iron deficiency? | It reflects body stores before transport iron (serum iron/transferrin) changes |
| Why is B12 deficiency dangerous even when anemia is corrected by folate? | SACD (neurological damage) continues because it depends on deoxyadenosylcobalamin, not folate |
| Why does B12 deficiency cause folate-responsive anemia? | Methylfolate trap - THF cannot be regenerated; large exogenous folate bypasses this via DHFR |
| Why take iron on an empty stomach? | Maximum absorption; food, especially calcium and tannins, chelates iron and reduces uptake |
| Why are TIBC and transferrin elevated in iron deficiency? | Compensatory upregulation of transferrin synthesis by liver to capture available iron |
| Why is parenteral iron dangerous? | Risk of anaphylaxis (especially iron dextran), iron overload, hemosiderosis |
| Why is folate deficiency more rapidly symptomatic than B12 deficiency? | Body folate stores last only 3-4 months vs. B12 stores lasting 3-5 years |
Q38. Drug interactions to know:
| Drug | Interaction with Iron |
|---|
| Tetracyclines | Form insoluble chelate; iron reduces absorption of tetracyclines AND vice versa |
| Fluoroquinolones (ciprofloxacin) | Same chelation mechanism |
| Levodopa | Iron chelates levodopa, reducing its absorption |
| Levothyroxine | Iron impairs absorption; separate by 4 hours |
| Antacids/PPIs | Raise pH → reduce Fe²⁺ formation → less absorption |
Q39. Differentiate the three nutritional anemias:
| Feature | Iron Deficiency | Folate Deficiency | B12 Deficiency |
|---|
| MCV | ↓ (microcytic) | ↑ (macrocytic) | ↑ (macrocytic) |
| Peripheral smear | Hypochromic, microcytic | Megaloblastic, hyperseg. neutrophils | Megaloblastic, hyperseg. neutrophils |
| Neurological signs | None | None | SACD (posterior/lateral columns) |
| Serum ferritin | ↓ | Normal | Normal |
| Methylmalonic acid | Normal | Normal | ↑ |
| Homocysteine | Normal | ↑ | ↑ |
| Schilling test | Normal | Normal | Abnormal |
| Common cause | Blood loss | Dietary/pregnancy/drugs | Pernicious anemia/gastrectomy |
| Treatment | Ferrous sulfate | Folic acid 5 mg/day | IM B12 (cyanocobalamin) |
Q40. Classic exam viva traps:
- "Can you correct B12 deficiency anemia with folic acid?" - Yes hematologically, but neurological damage (SACD) progresses. Never do this - always treat B12 deficiency with B12.
- "Best indicator of iron stores" - Serum ferritin (not serum iron).
- "Best form of iron for oral use" - Ferrous sulfate (cheap, effective, high elemental iron content).
- "Why does iron therapy cause black stools?" - Unabsorbed iron reacts with intestinal sulfides to form iron sulfide (harmless, but must distinguish from melena).
- "First sign of response to iron therapy" - Reticulocytosis at 3-5 days.
- "Megaloblastic anemia with no neurological signs" - Think folate deficiency (not B12).
- "Darbepoetin vs epoetin alfa" - Darbepoetin has a longer half-life due to additional carbohydrate chains (hyperglycosylation), allowing less frequent dosing.